US Edition
News from pharmaceutical-technology.com
Information about Pharmaceutical-technology.com
Where is Pharmaceutical-technology.com located?Pharmaceutical-technology.com's WebsiteMedia Bias Ratings
Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top Pharmaceutical-technology.com News
Novo Nordisk · United StatesCollaboration of over one month has ended based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient...See the Story
Novo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 20%
61% Center coverage: 67 sources
Startups · RotterdamCAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 22, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a global strategic collaboration with…See the Story
Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers
62% Center coverage: 29 sources
FDA · United StatesThe U.S. Food and Drug Administration (FDA) on Friday approved Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Dupixent (dupilumab) for adult patients with bullous pemphigoid (BP), a rare, chronic autoimmune skin disorder. BP primarily affects elderly patients and is characterized by intense itch, painful blisters and lesions, and skin reddening. It can be chronic and relapsing with underlying type 2 inflammation. The b…See the Story
FDA Approves Regeneron Sanofi Treatment For Rare Autoimmune Skin Disorder - Regeneron Pharmaceuticals (NASDAQ:REGN), Sanofi (NASDAQ:SNY)
100% Center coverage: 5 sources
FDA Approves AstraZeneca And Daiichi Sankyo's Datroway For EGFR-Mutated Lung Cancer - AstraZeneca (NASDAQ:AZN)
67% Center coverage: 3 sources
